Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6323564 | 1.00 | CYP2D6 (0.54) | CYP2D6SLC6A3KCNH2SLC6A2SLC6A4 | |
| SCHEMBL1205146 | 1.00 | CYP2D6 (0.54) | CYP2D6SLC6A3KCNH2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL6282414 | 0.98 | CYP2D6 (0.52) | CYP2D6SLC6A3KCNH2SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL6668150 | 0.98 | CYP2D6 (0.52) | CYP2D6SLC6A3KCNH2SLC6A2SLC6A4 | |
| SCHEMBL23366934 | 0.83 | CYP2D6 (0.45) | CYP2D6SLC6A3KCNH2SLC6A2SLC6A4 | |
| SCHEMBL14353740 | 0.82 | HRH3 (0.47) | CYP2D6SLC6A3KCNH2SLC6A2SLC6A4 | |
| SCHEMBL7040753 | 0.82 | KDM4E (0.46) | CYP2D6SLC6A3KCNH2SLC6A2SLC6A4 | |
| SCHEMBL10891883 | 0.82 | HIF1A (0.50) | CYP2D6CYP3A4TSHRKDM4EHIF1A | |
| SCHEMBL6633134 | 0.81 | TSHR (0.41) | CYP2D6SLC6A3KCNH2SLC6A2SLC6A4 | |
| SCHEMBL22480688 | 0.81 | ADRB2 (0.58) | CYP2D6CYP3A4TSHRKDM4EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044056-B1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| WO-2010100144-A1 | FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| EP-1758585-A4 | HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-7476666-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080015187-A1 | Hiv Integrase Inhibitors | MERCK SHARP & DOHME CORP. | 2008-01-17 | — | — | US | disclosed |
| WO-2008006583-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
| EP-1467999-A1 | OXOTHIENO[3,2-B]PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1465895-A2 | 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1458719-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | disclosed |
| US-20040110787-A1 | Heteroaryl-ethanolamine derivatives as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004022567-A1 | HETEROARYL-ETHANOLAMINE DERIVATIVES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2003059912-A1 | OXOTHIENO (3, 2-B) PYRIDINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059878-A2 | THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059911-A2 | 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003053971-A1 | PYRIDOQUINOXALINE ANTIVIRALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110787-A1 | Heteroaryl-ethanolamine derivatives as antiviral agents | RPL35, ZC3HAV1, RPL5 | CYP2D6 1952/4885SLC6A3 731/4885KCNH2 2524/4885 |
| US-20040138449-A1 | Antiviral agents | IRF3, IFNAR1, EIF2AK2 | CYP2D6 1364/4885SLC6A3 1295/4885KCNH2 766/4885 |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | ALK, ACVR1, MUSK | CYP2D6 1237/4885SLC6A3 4275/4885KCNH2 2701/4885 |
| US-20080015187-A1 | Hiv Integrase Inhibitors | REV1, ZC3HAV1, PNP | CYP2D6 2041/4885SLC6A3 4241/4885KCNH2 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.